LAWRENCE, Mass., Aug. 4, 2017 /PRNewswire/ -- NxStage
Medical, Inc. (Nasdaq: NXTM), a leading medical technology
company focused on advancing renal care, joins over one hundred
NxStage patients in celebrating their ten-year anniversary on home
hemodialysis with the NxStage® System
One™.
"The number of personal goals I've achieved over the past 10
years would not have been possible without the NxStage System One,"
said Jenna Smith, a NxStage patient
for 13 years. "I'm extremely thankful to have found home
hemodialysis because my treatment fits into my life whenever and
wherever I want, instead of the other way around."
The NxStage System One is the first and only truly portable
hemodialysis system cleared in the United States for home
hemodialysis and home nocturnal hemodialysis. Its simple and
portable design provides a range of hemodialysis therapy options
including more frequent treatments at home during the daytime or at
night, while sleeping.
More frequent home hemodialysis is associated with clinical
benefits and improved outcomes, including a 13% lower risk of death
compared to traditional in-center hemodialysis1, and an
11% reduction in left ventricular hypertrophy, reducing stress on
the heart.2,3 More frequent home hemodialysis is also
linked to an 87% improvement in recovery time after
treatment.4
"A little over a decade ago, NxStage introduced a revolutionary
dialysis machine, the System One, to give patients the freedom and
flexibility to do their dialysis when and where they wanted.
It's incredibly rewarding to join over one hundred of our patients
in celebrating their ten plus year anniversary on HHD," said
Jeff Burbank, Founder and CEO of
NxStage Medical, Inc. "This milestone is a testament to both the
strength of our patients and the life changing benefits of our
therapy."
For more information on NxStage or the System One, visit:
www.NxStage.com.
The NxStage System One is a prescription device and, like all
medical devices, involves some risks. The risks associated with
hemodialysis treatments in any environment include, but are not
limited to, high blood pressure, fluid overload, low blood
pressure, heart-related issues, and vascular access complications.
The medical devices used in hemodialysis therapies may add
additional risks including air entering the bloodstream, and blood
loss due to clotting or accidental disconnection of the blood
tubing set. Patients should consult with their doctor to understand
the risks and responsibilities of home and/or more frequent
hemodialysis using the NxStage System One. Additionally, the
reported benefits of home and/or more frequent hemodialysis may not
be experienced by all patients. Patients and providers are
encouraged to contact their state regulators to discuss
state-specific regulations that may impact dialysis in the skilled
nursing facility setting.
About the NxStage System One
The NxStage System
One is the first and only truly portable hemodialysis system
cleared specifically by the FDA for home hemodialysis and
home nocturnal hemodialysis. The simplicity and revolutionary size
(just over a foot tall) are intended to allow convenient use in
patients' homes and give patients the freedom to travel with their
therapy. When combined with the NxStage PureFlow™ SL Dialysis
Preparation System, patients are able to further simplify, using
ordinary tap water to create dialysis fluid on-site on-demand.
Unlike conventional hemodialysis systems, the System One family of
products requires no special infrastructure to operate. Under the
guidance of their physician, patients can use the NxStage System
One, with their trained partners, where, how and when it best meets
their needs, including while they are sleeping - at home or on
vacation and at a medically appropriate treatment frequency. In
addition, NxStage's Nx2me Connected Health® platform collects
important NxStage System One and patient information for flexible
viewing, monitoring and reporting that may improve patient
management and patient retention, as well as simplify alternative
site care. The System One is also used to provide a range of
flexible therapy options in more traditional care settings such as
hospitals, dialysis centers and skilled nursing facilities. Its
safety and performance have been demonstrated by experience with
more than 14 million treatments with over 30 thousand patients
around the world. www.nxstage.com.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical
technology company, headquartered in Lawrence, Massachusetts, USA, that develops,
manufactures and markets innovative products for the treatment of
ESRD and acute kidney failure. NxStage also has established a small
number of dialysis clinics committed to the development of
innovative care delivery models for patients with ESRD. For more
information on NxStage and its products and services, please visit
the Company's websites at www.nxstage.com and
www.nxstagekidneycare.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this release that are not clearly
historical in nature are forward-looking, and the words
"anticipate," "believe," "expect," "estimate," "plan," and similar
expressions are generally intended to identify forward-looking
statements. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors including those that are discussed in
NxStage's filings with the Securities and Exchange Commission,
including its Quarterly Report on Form 10-Q for the quarter ended
March 31, 2017. NxStage is under no
obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Media contact:
Kristen
K. Sheppard, Esq.
ksheppard@nxstage.com
References:
1. Weinhandl ED, Lie J, Gilbertson DT, Arneson TJ, Collins AJ.
Survival in daily home hemodialysis and matched thrice-weekly
in-center hemodialysis patients. J Am Soc Nephrol.
2012;33(5):895-904.
2. FHN Trial Group. In-center hemodialysis six times per week
versus three times per week. N Engl J Med.
2010;363(24):2287-2300.
3. Culleton BF, Pannier B, Guerin AP, et al. Alterations of left
ventricular hypertrophy in and survival of patients receiving
hemodialysis: follow-up of an interventional study. J Am Soc
Nephrol. 2001;12(12):2759-2767.
4. Jaber BL, Lee Y, Collins AJ, et al. Effect of daily hemodialysis
on depressive symptoms and post dialysis recovery time: interim
report from the FREEDOM (Following Rehabilitation, Economics and
Everday-Dialysis Outcome Measurements) Study. Am J Kidney Dis.
2010;56(3):531-539.
View original content with
multimedia:http://www.prnewswire.com/news-releases/over-one-hundred-nxstage-patients-celebrate-ten-year-anniversary-on-home-hemodialysis-with-the-system-one-300499779.html
SOURCE NxStage Medical, Inc.